ATE278795T1 - Herpesviren für die modulation einer immunantwort - Google Patents

Herpesviren für die modulation einer immunantwort

Info

Publication number
ATE278795T1
ATE278795T1 AT01919668T AT01919668T ATE278795T1 AT E278795 T1 ATE278795 T1 AT E278795T1 AT 01919668 T AT01919668 T AT 01919668T AT 01919668 T AT01919668 T AT 01919668T AT E278795 T1 ATE278795 T1 AT E278795T1
Authority
AT
Austria
Prior art keywords
modulating
immune response
herpes viruses
virus
functional
Prior art date
Application number
AT01919668T
Other languages
English (en)
Inventor
Robert Stuart Coffin
Original Assignee
Biovex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovex Ltd filed Critical Biovex Ltd
Application granted granted Critical
Publication of ATE278795T1 publication Critical patent/ATE278795T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01919668T 2000-04-12 2001-04-12 Herpesviren für die modulation einer immunantwort ATE278795T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0009079.5A GB0009079D0 (en) 2000-04-12 2000-04-12 Herpes viruses for immune modulation
PCT/GB2001/001666 WO2001077358A2 (en) 2000-04-12 2001-04-12 Herpes viruses for immune modulation

Publications (1)

Publication Number Publication Date
ATE278795T1 true ATE278795T1 (de) 2004-10-15

Family

ID=9889816

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01919668T ATE278795T1 (de) 2000-04-12 2001-04-12 Herpesviren für die modulation einer immunantwort

Country Status (18)

Country Link
EP (1) EP1272652B1 (de)
JP (2) JP2003530369A (de)
KR (1) KR100805771B1 (de)
CN (1) CN100351385C (de)
AT (1) ATE278795T1 (de)
AU (1) AU783395B2 (de)
BR (1) BR0109928A (de)
CA (1) CA2405458C (de)
DE (1) DE60106222T2 (de)
DK (1) DK1272652T3 (de)
ES (1) ES2230291T3 (de)
GB (2) GB0009079D0 (de)
HK (1) HK1048136B (de)
IL (2) IL152055A0 (de)
MX (1) MXPA02010074A (de)
PT (1) PT1272652E (de)
WO (1) WO2001077358A2 (de)
ZA (1) ZA200207920B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063851B2 (en) 2000-04-12 2006-06-20 Biovex Limited Herpes viruses for immune modulation
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
US7695725B2 (en) * 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US20100008944A1 (en) * 2005-07-29 2010-01-14 President And Fellows Of Harvard College Herpes simplex virus mutant and uses therefore
CN102146418B (zh) * 2010-02-09 2014-01-15 武汉滨会生物科技有限公司 重组ⅱ型单纯疱疹病毒载体及其制备方法、重组病毒、药物组合物及应用
CN105219739A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
CN105219738A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
JP7075653B2 (ja) * 2018-02-06 2022-05-26 学校法人福岡大学 αヘルペスウイルス感染を処置する方法及び医薬組成物
CN109161561A (zh) * 2018-08-09 2019-01-08 湖北科技学院 一种选择性杀灭前列腺癌细胞的新型溶瘤病毒及其构建方法
EP4511049A4 (de) * 2022-04-18 2026-04-29 Candel Therapeutics Inc Zusammensetzungen und verfahren für virale vektoren
AU2023319760A1 (en) * 2022-08-05 2025-02-13 Immvira Co., Limited Replication incompetent herpes simplex virus type 1 viral vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763217A (en) * 1993-11-10 1998-06-09 University Of British Columbia Method of using, process of preparing and composition comprising recombinant herpesvirus vectors
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US5998174A (en) * 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9801930D0 (en) * 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
GB9810904D0 (en) * 1998-05-20 1998-07-22 Univ London Mutant herpes simplex viruses and uses thereof
GB9816781D0 (en) * 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells

Also Published As

Publication number Publication date
GB2376687B (en) 2004-06-09
GB0009079D0 (en) 2000-05-31
JP2012188440A (ja) 2012-10-04
MXPA02010074A (es) 2003-04-25
AU4672801A (en) 2001-10-23
EP1272652B1 (de) 2004-10-06
JP5543528B2 (ja) 2014-07-09
GB0224000D0 (en) 2002-11-20
BR0109928A (pt) 2003-05-27
CN1439056A (zh) 2003-08-27
WO2001077358A3 (en) 2002-03-14
HK1048136A1 (en) 2003-03-21
IL152055A (en) 2010-12-30
CA2405458A1 (en) 2001-10-18
CA2405458C (en) 2011-08-30
KR100805771B1 (ko) 2008-02-21
IL152055A0 (en) 2003-05-29
PT1272652E (pt) 2004-12-31
DK1272652T3 (da) 2005-02-14
WO2001077358A2 (en) 2001-10-18
AU783395B2 (en) 2005-10-20
KR20030047883A (ko) 2003-06-18
JP2003530369A (ja) 2003-10-14
DE60106222D1 (de) 2004-11-11
CN100351385C (zh) 2007-11-28
DE60106222T2 (de) 2005-10-13
ZA200207920B (en) 2004-07-08
HK1048136B (zh) 2004-12-03
EP1272652A2 (de) 2003-01-08
GB2376687A (en) 2002-12-24
ES2230291T3 (es) 2005-05-01

Similar Documents

Publication Publication Date Title
EP1504112A4 (de) Entwicklung einer vakzine zur prävention von infektionen mit dem filovirus bei primaten
DE60106222D1 (de) Herpesviren für die modulation einer immunantwort
DE50214416D1 (de) Vermehrung von viren in zellkultur
UY26555A1 (es) Composición farmacéutica para modulación inmunológica y preparación de vacunas
WO2003063899A3 (en) Vaccine adjuvant based on a cd4 0 ligand
DK2239269T3 (da) Anvendelse af peptider afledt af copolymer-1 som molekylvægtsmarkører
MXPA02007478A (es) Vacuna contra el virus de inmunodeficiencia humana.
WO2002032943A3 (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
DE69936337D1 (de) Verfahren zur entwicklung von einem hiv impfstoff
WO2003041735A3 (en) Composotion comprising inhibitors of the notch signalling pathway for the modulation of the immune system
ATE439441T1 (de) Veränderte, fluoreszierende proteine
DK0771213T3 (da) Haemophilus influenza adhærens- og penetrationsproteiner
AU2001263269A1 (en) Long wavelength engineered fluorescent proteins
WO2004091524A3 (en) Respiratory virus vaccines
WO2002030964A3 (en) Comparative ligand mapping from mhc positive cells
DE69940731D1 (de) Zusammensetzungen und verfahren zur modulation einer immunantwort auf ein antigen durch verabreichung von zytokine-beladenen zellen
WO2003053338A3 (en) Novel chimeric rev, tat, and nef antigens
ATE386049T1 (de) Epstein-barr virus type b ctl epitopen
ES2155239T3 (es) Compuestos antiviricos.
ATE285250T1 (de) Verwendung von polymeren der hyaluronsäure zur mukosalen freigabe von impfstoffen und adjuvantien
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
ATE346087T1 (de) Hepatitis e-virus aus dem schwein und dessen verwendungen
BR9915703B1 (pt) mutante do vìrus da raiva recombinante, e, vacina anti-rábica atenuada viva.
ATE374622T1 (de) Genetische impstoffe mit adjuvans

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1272652

Country of ref document: EP